Apnimed Inc.

07/30/2026 | Press release | Distributed by Public on 07/30/2026 18:16

Additional Securities Registration Statement (Form S-1MEF)

As filed with the Securities and Exchange Commission on July 30, 2026.

Registration No. 333-     

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Apnimed, Inc.

(Exact name of registrant as specified in its charter)

Delaware

2834

82-1910611

(State or other jurisdiction of
incorporation or organization)

(Primary Standard Industrial
Classification Code Number)

(I.R.S. Employer
Identification No.)

Apnimed, Inc.

39 John F. Kennedy Street, 4th Floor

Cambridge, MA 02138

(617) 500-8880

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Kevin R. Lind

Chief Executive Officer

39 John F. Kennedy Street, 4th Floor

Cambridge, MA 02138

(617) 500-8880

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Rachael Bushey

Justin Platt

Goodwin Procter LLP

3025 John F Kennedy Blvd,

Philadelphia, PA 19104

(445) 207-7800

Ilir Mujalovic

Harald Halbhuber

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, NY 10006

(212) 225-2043

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐

ACTIVE/208710915.2

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-297377)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

ACTIVE/208710915.2

EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"), for the sole purpose of increasing the aggregate number of shares of common stock offered by Apnimed, Inc. (the "Registrant") by 2,300,000 shares, 300,000 of which are subject to purchase upon exercise of the underwriters' option to purchase additional shares of the Registrant's common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-297377), filed by the Registrant with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act, including all amendments and exhibits thereto (the "Prior Registration Statement"), which was declared effective by the Commission on July 30, 2026, are incorporated by reference into this Registration Statement.

The additional shares of common stock that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 of the Prior Registration Statement.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith or incorporated by reference herein.

EXHIBIT INDEX

Exhibit
No.

Exhibit Index

5.1

23.1

23.2

24.1*

Power of Attorney

107

*

Previously included on the signature page to the Prior Registration Statement, originally filed with the Securities and Exchange Commission on July 10, 2026 and incorporated by reference herein.

ACTIVE/208710915.2

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts on the 30th day of July, 2026.

Apnimed, Inc.

By:

/s/ Kevin R. Lind

Kevin R. Lind

Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in their capacities and on the date indicated.

Signature

Title

/s/ Kevin R. Lind

Kevin R. Lind

Chief Executive Officer and Director

(Principal Executive Officer)

/s/ Michael Kelly

Michael Kelly

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

*

Paul Sekhri

Director, Board Chair

*

Lawrence G. Miller, M.D.

Director, Vice Chair

*

Chris Dimitropoulos

Director

*

Paul Fonteyne

Director

*

Gary Sender

Director

*

William (BJ) Jones, Jr.

Director

*By:

/s/ Kevin R. Lind

Kevin R. Lind

Attorney-in-Fact

ACTIVE/208710915.2

Apnimed Inc. published this content on July 30, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 31, 2026 at 00:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]